HPB Surgery Unit, Queen Elizabeth Hospital, Birmingham, UK.
Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
BJS Open. 2023 Sep 5;7(5). doi: 10.1093/bjsopen/zrad090.
To determine the incidence and risk factors for postoperative complications and prolonged hospital stay after adrenalectomy for phaeochromocytoma.
Demographics, perioperative outcomes and complications were evaluated for consecutive patients who underwent adrenalectomy for phaeochromocytoma from 2012 to 2020 in nine high-volume UK centres. Odds ratios were calculated using multivariable models. The primary outcome was postoperative complications according to the Clavien---Dindo classification and secondary outcome was duration of hospital stay.
Data were available for 406 patients (female n = 221, 54.4 per cent). Two patients (0.5 per cent) had perioperative death, whilst 148 complications were recorded in 109 (26.8 per cent) patients. On adjusted analysis, the age-adjusted Charlson Co-morbidity Index ≥3 (OR 8.09, 95 per cent c.i. 2.31 to 29.63, P = 0.001), laparoscopic converted to open (OR 10.34, 95 per cent c.i. 3.24 to 36.23, P <0.001), and open surgery (OR 11.69, 95 per cent c.i. 4.52 to 32.55, P <0.001) were independently associated with postoperative complications. Overall, 97 of 430 (22.5 per cent) had a duration of stay ≥5 days and this was associated with an age-adjusted Charlson Co-morbidity Index ≥3 (OR 4.31, 95 per cent c.i. 1.08 to 18.26, P = 0.042), tumour size (OR 1.15, 95 per cent c.i. 1.05 to 1.28, P = 0.006), laparoscopic converted to open (OR 32.11, 95 per cent c.i. 9.2 to 137.77, P <0.001), and open surgery (OR 28.01, 95 per cent c.i. 10.52 to 83.97, P <0.001).
Adrenalectomy for phaeochromocytoma is associated with a very low mortality rate, whilst postoperative complications are common. Several risk factors, including co-morbidities and operative approach, are independently associated with postoperative complications and/or prolonged hospitalization, and should be considered when counselling patients.
确定嗜铬细胞瘤肾上腺切除术术后并发症和住院时间延长的发生率和危险因素。
评估了 2012 年至 2020 年在英国 9 个高容量中心接受嗜铬细胞瘤肾上腺切除术的连续患者的人口统计学、围手术期结果和并发症。使用多变量模型计算比值比。主要结局是根据 Clavien-Dindo 分类的术后并发症,次要结局是住院时间。
406 名患者的数据(女性 n=221,54.4%)可用。2 名患者(0.5%)在围手术期死亡,109 名患者(26.8%)中记录了 148 种并发症。调整分析显示,年龄调整Charlson 合并症指数≥3(OR 8.09,95%置信区间 2.31 至 29.63,P=0.001)、腹腔镜转为开放(OR 10.34,95%置信区间 3.24 至 36.23,P<0.001)和开放手术(OR 11.69,95%置信区间 4.52 至 32.55,P<0.001)与术后并发症独立相关。总体而言,430 名患者中有 97 名(22.5%)的住院时间≥5 天,这与年龄调整Charlson 合并症指数≥3(OR 4.31,95%置信区间 1.08 至 18.26,P=0.042)、肿瘤大小(OR 1.15,95%置信区间 1.05 至 1.28,P=0.006)、腹腔镜转为开放(OR 32.11,95%置信区间 9.2 至 137.77,P<0.001)和开放手术(OR 28.01,95%置信区间 10.52 至 83.97,P<0.001)有关。
嗜铬细胞瘤肾上腺切除术的死亡率非常低,而术后并发症很常见。包括合并症和手术方法在内的几个危险因素与术后并发症和/或住院时间延长独立相关,在为患者提供咨询时应予以考虑。